Green Thumb Industries Inc.

Green Thumb Industries Inc. Earnings Recaps

GTBIF Health Care 2 recaps
Next earnings: February 24, 2027 (estimated) · full calendar
Q3 2026 Nov 6, 2026

Green Thumb shares fell 4.7% after the earnings call, with persistent pricing pressure and unresolved federal tax and rescheduling uncertainty likely weighing on the outlook. Revenue grew year over year, but management offered no near-term resolution to those uncertainties.

Key takeaways
  • Q3 revenue was $324 million, up 11% year over year.
  • Normalized EBITDA was $89 million, about 28% of revenue; the margin was in line with the year-ago quarter despite pricing pressure in several markets.
  • Cash from operations was $58 million, up from Q2, and the company ended the quarter with $316 million in cash.
  • Federal rescheduling remains pending, and timing for 280E tax guidance is uncertain; management said Section 280E no longer applies to its medical business.
  • The board authorized a new $50 million share repurchase program; the company said it had returned more than $200 million to shareholders since Q4 2023.
Q2 2026 Aug 7, 2026

Shares of Green Thumb Industries fell 5.5% after the earnings release, driven by investor concerns around continued price compression and a cautious outlook despite stable revenue growth.

Key takeaways
  • Q2 revenue grew 5% year-over-year to $307 million, reflecting underlying business scale but modest top-line momentum.
  • Normalized EBITDA reached $84 million, or approximately 28% of revenue, indicating margin pressure amid ongoing price compression.
  • Cash flow from operations was $29 million, supporting ongoing share repurchases totaling roughly $200 million returned since late 2023.
  • Management highlighted regulatory progress and potential federal rescheduling as long-term catalysts, but provided no firm near-term guidance upgrades.
  • Early signs of price stabilization in select markets were noted, though competitive dynamics and price pressure persist, keeping near-term outlook cautious.